Hudson, who was pushed out just two months before his tenure was up for renewal, did not respond to a Reuters request for comment. Sanofi, among the world's largest vaccine makers, released a string of underwhelming trial updates last year while pursuing bolt-on acquisitions in search of new medicines to help drive growth once its blockbuster asthma drug Dupixent loses key patents in the early 2030s.
Hudson had been hired with a mandate to revive the company's drug pipeline and share price but has struggled to reduce Sanofi's dependence on its star eczema treatment Dupixent, drawing pressure from investors.
Shareholders have seen a 33% return on their investment, including dividends, since September 2019 when Hudson took over, according to LSEG data.
That is significantly lower than UK-based rivals AstraZeneca and GSK, which saw returns of 133% and 65% respectively during the same period.
Sanofi said in late January that its vaccines sales would be "slightly negative" this year, partly due to U.S. policy changes under President Donald Trump.
SANOFI SEEKS ITS 'NEXT GROWTH CYCLE' UNDER NEW CEO
Sanofi said in a statement that Hudson would step down as of February 17, while Garijo will take the role at the end of the group's shareholder meeting on April 29. Sanofi board member Olivier Charmeil will serve as acting CEO during the transition.
Garijo previously worked for 15 years at Sanofi and was a board member at French cosmetics giant L'Oreal.
"She has the experience and profile to accelerate the pace, strengthen the quality of execution of strategy and lead the next growth cycle of the company," Sanofi chairman Frederic Oudea said in a statement.
JP Morgan analysts said that Garijo was expected to bring in greater discipline at Sanofi and speed up preparations for the drugmakers future beyond Dupixent, with a focus on boosting R&D productivity.
Hudson had said in January that 2026 would be a good time for deal making after the firm forecast high-single-digit overall sales growth this year, despite an expected drop in vaccine sales linked to vaccine scepticism in the United States.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.